We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+18.23%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.29B
AUM Growth
+$158M
Cap. Flow
+$36.7M
Cap. Flow %
2.84%
Top 10 Hldgs %
39.6%
Holding
109
New
17
Increased
24
Reduced
36
Closed
22

Top Buys

Rank Stock Value
1
GRFS
Grifois
GRFS
+$36.8M
2
SNY icon
Sanofi
SNY
+$29.7M
3
QDEL icon
QuidelOrtho
QDEL
+$27.8M
4
KRYS icon
Krystal Biotech
KRYS
+$17.5M
5
LLY icon
Eli Lilly
LLY
+$17.4M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$24.3M
2
NRIX icon
Nurix Therapeutics
NRIX
+$22.4M
3
PEN icon
Penumbra
PEN
+$22.2M
4
HUM icon
Humana
HUM
+$16.6M
5
GSK icon
GSK
GSK
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.11%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$88.9M 6.89%
+900,000
New +$88.4M
IOVA icon
2
Iovance Biotherapeutics
IOVA
$2.23B
$80.1M 6.2%
8,528,500
+980,500
+13% +$9.29M
TGTX icon
3
TG Therapeutics
TGTX
$8.58B
$59.3M 4.59%
2,534,540
-1,111,022
-30% -$24.3M
TERN
4
DELISTED
Terns Pharmaceuticals
TERN
$51.9M 4.02%
6,223,544
+1,275,806
+26% +$10.5M
AXGN icon
5
Axogen
AXGN
$2.1B
$42.1M 3.26%
3,005,943
-299,872
-9% -$3.32M
GRFS
6
Grifois
GRFS
$5.16B
$40.2M 3.11%
+4,521,703
New +$36.8M
KRYS icon
7
Krystal Biotech
KRYS
$9.88B
$39.5M 3.06%
216,979
+90,979
+72% +$17.5M
CCCC icon
8
C4 Therapeutics
CCCC
$376M
$37.6M 2.91%
6,603,996
+2,552,000
+63% +$15.4M
UTHR icon
9
United Therapeutics
UTHR
$26.3B
$36.5M 2.83%
101,894
-39,605
-28% -$13.4M
SNY icon
10
Sanofi
SNY
$104B
$35.3M 2.73%
612,000
+549,500
+879% +$29.7M
ORGO icon
11
Organogenesis Holdings
ORGO
$308M
$33.9M 2.62%
11,839,876
+320,922
+3% +$900K
IDYA icon
12
IDEAYA Biosciences
IDYA
$3.41B
$33.2M 2.57%
1,049,314
+355,245
+51% +$13.5M
RVMD icon
13
Revolution Medicines
RVMD
$40.2B
$32M 2.47%
704,584
-151,594
-18% -$6.6M
QDEL icon
14
QuidelOrtho
QDEL
$1.09B
$31.3M 2.42%
+686,000
New +$27.8M
EPIX
15
DELISTED
ESSA Pharma
EPIX
$26M 2.01%
4,288,167
+77,630
+2% +$426K
JSPR icon
16
Jasper Therapeutics
JSPR
$22.9M
$25.3M 1.96%
1,343,665
+67,475
+5% +$1.34M
SRDX
17
DELISTED
Surmodics
SRDX
$24.7M 1.91%
637,698
-144,079
-18% -$5.83M
NRIX icon
18
Nurix Therapeutics
NRIX
$2.43B
$23.9M 1.85%
1,065,834
-990,082
-48% -$22.4M
TXG icon
19
10x Genomics
TXG
$5.87B
$21.5M 1.66%
951,000
+232,000
+32% +$4.8M
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$1.84B
$21M 1.63%
1,090,984
+264,484
+32% +$5.46M
MRUS
21
DELISTED
Merus
MRUS
$19.9M 1.54%
398,321
+22,000
+6% +$1.15M
CSTL icon
22
Castle Biosciences
CSTL
$749M
$18.9M 1.46%
662,332
-191,296
-22% -$4.87M
FOCL
23
EDAP TMS S.A.
FOCL
$226M
$18.6M 1.44%
7,309,254
+15,526
+0.2% +$63.6K
ONC
24
BeOne Medicines Ltd
ONC
$33.8B
$18.6M 1.44%
82,750
-54,950
-40% -$9.89M
CELC icon
25
Celcuity
CELC
$4.03B
$18.6M 1.44%
1,245,387
+34,200
+3% +$564K
1
2 3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Soleus Capital Management held 109 positions worth $1.29B, up 14% from $1.13B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Soleus Capital Management's Q3 2024 filing shows 17 new, 24 increased, 36 reduced and 22 closed positions. Its largest new stake was Grifois: 4,521,703 shares worth $40.2M. The largest sale was TG Therapeutics, an estimated $24.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier, followed by Consumer Staples.

  • Soleus Capital Management's largest Q3 2024 buy was Grifois: 4,521,703 shares worth $40.2M.
  • Soleus Capital Management added most to Sanofi in Q3 2024, an estimated $29.7M increase.
  • Soleus Capital Management's biggest Q3 2024 reduction was TG Therapeutics, cutting an estimated $24.3M.
  • Soleus Capital Management fully exited Penumbra in Q3 2024, selling an estimated $22.2M.
  • Soleus Capital Management's ten largest holdings make up 40% of its $1.29B portfolio in Q3 2024.
  • Soleus Capital Management opened 17 new positions and closed 22 in Q3 2024.
  • Soleus Capital Management's portfolio value rose 14% quarter-over-quarter to $1.29B.

Based on Soleus Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.